JP2018534329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534329A5 JP2018534329A5 JP2018526187A JP2018526187A JP2018534329A5 JP 2018534329 A5 JP2018534329 A5 JP 2018534329A5 JP 2018526187 A JP2018526187 A JP 2018526187A JP 2018526187 A JP2018526187 A JP 2018526187A JP 2018534329 A5 JP2018534329 A5 JP 2018534329A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- acceptable salt
- alkyl
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 238000000034 method Methods 0.000 claims 13
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 9
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 9
- -1 hydrate Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 4
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 4
- 102000002791 Interleukin-8B Receptors Human genes 0.000 claims 4
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 4
- 102000017578 LAG3 Human genes 0.000 claims 4
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 claims 4
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 claims 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 4
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 150000001204 N-oxides Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims 2
- 102000002627 4-1BB Ligand Human genes 0.000 claims 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims 2
- 102100022464 5'-nucleotidase Human genes 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000016680 Dioxygenases Human genes 0.000 claims 2
- 108010028143 Dioxygenases Proteins 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 102000002698 KIR Receptors Human genes 0.000 claims 2
- 108010043610 KIR Receptors Proteins 0.000 claims 2
- 101150069255 KLRC1 gene Proteins 0.000 claims 2
- 101150030213 Lag3 gene Proteins 0.000 claims 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 2
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims 2
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 2
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 2
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 claims 2
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 claims 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 229940124650 anti-cancer therapies Drugs 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000011393 cytotoxic chemotherapy Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 2
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 229940127130 immunocytokine Drugs 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000037883 airway inflammation Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000007676 prostate small cell carcinoma Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257529P | 2015-11-19 | 2015-11-19 | |
| US62/257,529 | 2015-11-19 | ||
| PCT/US2016/062427 WO2017087610A1 (en) | 2015-11-19 | 2016-11-17 | Inhibitors of cxcr2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534329A JP2018534329A (ja) | 2018-11-22 |
| JP2018534329A5 true JP2018534329A5 (OSRAM) | 2019-12-26 |
| JP6901479B2 JP6901479B2 (ja) | 2021-07-14 |
Family
ID=58717757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526187A Active JP6901479B2 (ja) | 2015-11-19 | 2016-11-17 | Ｃｘｃｒ２の阻害剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9809581B2 (OSRAM) |
| EP (1) | EP3377059B1 (OSRAM) |
| JP (1) | JP6901479B2 (OSRAM) |
| KR (1) | KR102725791B1 (OSRAM) |
| CN (1) | CN108601766B (OSRAM) |
| AR (1) | AR106757A1 (OSRAM) |
| AU (1) | AU2016355654B2 (OSRAM) |
| BR (1) | BR112018010118B1 (OSRAM) |
| CA (1) | CA3005737C (OSRAM) |
| DK (1) | DK3377059T3 (OSRAM) |
| EA (1) | EA035417B1 (OSRAM) |
| ES (1) | ES2841912T3 (OSRAM) |
| IL (1) | IL259354B (OSRAM) |
| MX (1) | MX382779B (OSRAM) |
| PL (1) | PL3377059T3 (OSRAM) |
| PT (1) | PT3377059T (OSRAM) |
| SG (1) | SG11201804136SA (OSRAM) |
| TW (1) | TWI724056B (OSRAM) |
| WO (1) | WO2017087610A1 (OSRAM) |
| ZA (1) | ZA201803436B (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| CN110753555A (zh) | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| WO2018200571A1 (en) | 2017-04-25 | 2018-11-01 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1h-indene analogs and methods using same |
| RU2020106383A (ru) | 2017-08-14 | 2021-09-16 | Аллерган, Инк. | 3,4-двузамещенные 3-циклобутен-1,2-дионы и их применение |
| IL275839B2 (en) * | 2018-01-08 | 2024-02-01 | Chemocentryx Inc | Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist |
| AU2019209432A1 (en) | 2018-01-22 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| CN111936518A (zh) | 2018-02-06 | 2020-11-13 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| CA3093851A1 (en) | 2018-03-29 | 2019-10-03 | Arbutus Biopharma Corporation | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same |
| NZ773164A (en) * | 2018-08-29 | 2025-07-25 | Chemocentryx Inc | Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors |
| GEP20237476B (en) | 2018-09-21 | 2023-03-27 | Pfizer | N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| AU2020272216A1 (en) * | 2019-04-08 | 2021-09-30 | Pi Industries Limited | Novel oxadiazole compounds for controlling or preventing phytopathogenic fungi |
| EP4524131A1 (en) * | 2019-05-15 | 2025-03-19 | AlonBio Ltd. | Small molecules for treating cancer, inhabiting chemokine activity and/or inducing cell death |
| CA3145303A1 (en) | 2019-07-10 | 2021-01-14 | Chemocentryx, Inc. | Indanes as pd-l1 inhibitors |
| CN112274511B (zh) * | 2019-07-22 | 2024-04-02 | 正大天晴药业集团股份有限公司 | 用于治疗移植物抗宿主病的喹啉衍生物 |
| EP4045036A4 (en) | 2019-10-16 | 2023-11-15 | ChemoCentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
| EP4045037A4 (en) | 2019-10-16 | 2023-11-15 | ChemoCentryx, Inc. | HETEROARYL-BIPHENYL AMINE FOR THE TREATMENT OF PD-L1 DISEASE |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN113018438B (zh) * | 2019-12-24 | 2022-06-17 | 四川大学 | Cxcr2抑制剂在制备治疗鼻咽癌的药物中的用途 |
| CN114929225B (zh) * | 2020-01-19 | 2024-06-28 | 正大天晴药业集团股份有限公司 | 用于治疗类风湿性关节炎的喹啉衍生物 |
| WO2021222818A2 (en) * | 2020-04-30 | 2021-11-04 | Gordon Erlinda M | Damage-targeted treatments of disease |
| CN113995839B (zh) * | 2021-10-11 | 2023-03-03 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Cxcr2抑制剂在改善肿瘤免疫微环境中的应用 |
| CN113952453B (zh) * | 2021-10-11 | 2023-01-24 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Cxcr2抑制剂在制备治疗肿瘤的药物中的应用 |
| WO2024144816A1 (en) * | 2022-12-30 | 2024-07-04 | Cantex Pharmaceuticals, Inc. | Treatment of immunologically cold solid tumors |
| WO2025149577A1 (en) * | 2024-01-11 | 2025-07-17 | Julius-Maximilians-Universitaet Wuerzburg | 18f-cxcr2 pet tracer |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268002A (en) | 1917-09-12 | 1918-05-28 | William M Goodwin | Measuring instrument. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US6166050A (en) | 1998-12-14 | 2000-12-26 | American Home Products Corporation | 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4 |
| AR033803A1 (es) | 2000-03-01 | 2004-01-07 | Smithkline Beecham Corp | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas |
| MXPA02011868A (es) | 2000-05-30 | 2003-04-10 | Smithkline Beecham Corp | Antagonistas de receptor de interleucina 8. |
| US20040132694A1 (en) | 2001-01-16 | 2004-07-08 | Palovich Michael R. | Il-8 receptor antagonists |
| US20040048897A1 (en) | 2001-01-16 | 2004-03-11 | Mccleland Brent | Il-8 receptor antagonists |
| US20030204085A1 (en) | 2001-02-02 | 2003-10-30 | Taveras Arthur G. | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists |
| NZ527947A (en) | 2001-02-02 | 2005-10-28 | Schering Corp | 3,4-di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists |
| US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| CZ20032831A3 (cs) * | 2001-04-16 | 2004-03-17 | Schering Corporation | 3,4-Disubstituované cyklobuten-1,2-diony |
| US20040097547A1 (en) | 2001-04-16 | 2004-05-20 | Taveras Arthur G. | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| CN100444839C (zh) | 2002-03-18 | 2008-12-24 | 先灵公司 | 式(i)化合物在制备治疗化学激活物中介的疾病的药物中的应用 |
| JP4440917B2 (ja) | 2003-04-18 | 2010-03-24 | シェーリング コーポレイション | ２−ヒドロキシ−ｎ，ｎ−ジメチル−３−［［２−（１（ｒ）−５−メチル−２−フラニル）プロピル］アミノ］−３，４−ジオキソ−１−シクロブテン−１−イル］アミノ］ベンズアミドの合成 |
| MY144657A (en) | 2004-01-30 | 2011-10-31 | Schering Corp | Crystalline polymorphs of a cxc-chemokine receptor ligand. |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| DE102005035742A1 (de) | 2005-07-29 | 2007-02-01 | Merck Patent Gmbh | Quadratsäurederivate II |
| EP2041107A1 (en) * | 2006-07-07 | 2009-04-01 | Schering Corporation | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| WO2008055570A1 (de) | 2006-11-07 | 2008-05-15 | Thyssenkrupp Drauz Nothelfer Gmbh | Verfahren und anlage zum herstellen von verstärkten blechplatinen |
| CA2680177A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| FR2915147B1 (fr) | 2007-04-17 | 2010-01-15 | Peugeot Citroen Automobiles Sa | Siege pour vehicule automobile convertible en siege enfant dos a la route et vehicule automobile associe. |
| MX2009013276A (es) | 2007-06-06 | 2010-01-25 | Novartis Ag | Compuestos anti-inflamatorios de ciclobutenodiona sustituida. |
| CN101932553A (zh) | 2007-07-03 | 2010-12-29 | 先灵公司 | 合成1,2-取代的3,4-二氧代-1-环丁烯化合物的方法和中间体 |
| CA2694268A1 (en) | 2007-07-05 | 2009-01-08 | Schering Corporation | Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
| WO2009012375A2 (en) | 2007-07-19 | 2009-01-22 | Wyeth | Squarate kinase inhibitors |
| CA2700841A1 (en) | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| WO2009073683A2 (en) | 2007-12-04 | 2009-06-11 | Schering Corporation | Methods of treating copd |
| EP2318369A1 (en) | 2008-06-24 | 2011-05-11 | TopoTarget A/S | Squaric acid derivatives as inhibitors of the nicotinamide |
| UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| EP2350067A2 (en) | 2008-10-16 | 2011-08-03 | Schering Corporation | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof |
| WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| WO2010091543A1 (en) * | 2009-02-10 | 2010-08-19 | Merck Sharp & Dohme Corp. | Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists |
| WO2010131147A1 (en) | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
| FR2961695B1 (fr) | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | Utilisation de composes dans le traitement ou la prevention de troubles cutanes |
| US8648118B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted amide functionalised phenols as medicaments |
| US8648070B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments |
| PT2760821T (pt) | 2011-09-02 | 2018-01-11 | Novartis Ag | Sal de colina de um composto anti-inflamatório de ciclobutenodiona substituída |
| FR2981936B1 (fr) | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| FR2981934B1 (fr) * | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| FR2981935B1 (fr) | 2011-10-28 | 2015-08-07 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| CA2873984A1 (en) | 2012-05-23 | 2013-11-28 | Stemergie Biotechnology Sa | Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof |
| WO2015170430A1 (ja) | 2014-05-08 | 2015-11-12 | 学校法人慶應義塾 | 大動脈解離後の炎症性障害抑制剤 |
| WO2016079049A1 (en) | 2014-11-17 | 2016-05-26 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| IL275839B2 (en) | 2018-01-08 | 2024-02-01 | Chemocentryx Inc | Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist |
-
2016
- 2016-11-14 TW TW105136997A patent/TWI724056B/zh active
- 2016-11-17 KR KR1020187017289A patent/KR102725791B1/ko active Active
- 2016-11-17 AU AU2016355654A patent/AU2016355654B2/en active Active
- 2016-11-17 WO PCT/US2016/062427 patent/WO2017087610A1/en not_active Ceased
- 2016-11-17 CA CA3005737A patent/CA3005737C/en active Active
- 2016-11-17 EP EP16867099.0A patent/EP3377059B1/en active Active
- 2016-11-17 CN CN201680068015.9A patent/CN108601766B/zh active Active
- 2016-11-17 EA EA201891211A patent/EA035417B1/ru not_active IP Right Cessation
- 2016-11-17 ES ES16867099T patent/ES2841912T3/es active Active
- 2016-11-17 PL PL16867099T patent/PL3377059T3/pl unknown
- 2016-11-17 BR BR112018010118-4A patent/BR112018010118B1/pt active IP Right Grant
- 2016-11-17 MX MX2018006148A patent/MX382779B/es unknown
- 2016-11-17 US US15/353,949 patent/US9809581B2/en active Active
- 2016-11-17 DK DK16867099.0T patent/DK3377059T3/da active
- 2016-11-17 SG SG11201804136SA patent/SG11201804136SA/en unknown
- 2016-11-17 JP JP2018526187A patent/JP6901479B2/ja active Active
- 2016-11-17 PT PT168670990T patent/PT3377059T/pt unknown
- 2016-11-18 AR ARP160103547A patent/AR106757A1/es active IP Right Grant
-
2017
- 2017-10-02 US US15/722,785 patent/US10370363B2/en active Active
-
2018
- 2018-05-14 IL IL259354A patent/IL259354B/en active IP Right Grant
- 2018-05-24 ZA ZA2018/03436A patent/ZA201803436B/en unknown
-
2019
- 2019-06-12 US US16/438,880 patent/US11040960B2/en active Active
-
2021
- 2021-04-29 US US17/243,872 patent/US11945805B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534329A5 (OSRAM) | ||
| JP2018538266A5 (OSRAM) | ||
| IL259342A (en) | Modulators of Kamkin receptors | |
| JP2017530959A5 (OSRAM) | ||
| JP2017507990A5 (OSRAM) | ||
| IL275333B2 (en) | Inhibitors of fibroblast activation protein | |
| JP2019527230A5 (OSRAM) | ||
| JP2016539096A5 (OSRAM) | ||
| JP2017536099A5 (OSRAM) | ||
| JP2013544846A5 (OSRAM) | ||
| JP2017537080A5 (OSRAM) | ||
| JP2017505116A5 (OSRAM) | ||
| JP2019518741A5 (OSRAM) | ||
| RU2018104092A (ru) | Бициклические лактамы и способы их применения | |
| JP2017538677A5 (OSRAM) | ||
| JP2017506234A5 (OSRAM) | ||
| JP2017533266A5 (OSRAM) | ||
| JP2017533912A5 (OSRAM) | ||
| JP2015529235A5 (OSRAM) | ||
| JP2018516994A5 (OSRAM) | ||
| JP2017510661A5 (OSRAM) | ||
| JP2017509586A5 (OSRAM) | ||
| JP2016516043A5 (OSRAM) | ||
| JP2019511564A5 (OSRAM) | ||
| JP2015504076A5 (OSRAM) |